SLCO6A1: A Promising Drug Target for Diabetes, Kidney Disease and Liver Disease

Target Name: SLCO6A1

NCBI ID: G133482

SLCO6A1

SLCO6A1: A Promising Drug Target for Diabetes, Kidney Disease and Liver Disease

SLCO6A1 (Sodium-ATPase Transmembrane protein 6 isoform) is a protein that plays an important role in organisms. It belongs to the cell membrane protein family and plays an important role on the cell membrane. Its main function is to promote the active transport of sodium ions inside and outside the cell. SLCO6A1 has a high expression level in humans and is mainly distributed in renal tubular and collecting duct epithelial cells, hepatocytes and leukocytes. At the same time, it has potential value in disease diagnosis and treatment, so it is considered a very promising drug target.

Functional and structural features of SLCO6A1

SLCO6A1 is a transmembrane protein whose main biological function is to promote the active transport of sodium ions inside and outside cells. In nerve cells, sodium ion balance has a crucial impact on neuron survival and action potential generation. SLCO6A1 realizes active transport of sodium ions on the nerve cell membrane through its ion channel channel, thereby maintaining the difference in sodium ion concentration inside and outside the cell. In addition, SLCO6A1 also plays an important role in cell metabolism regulation, cell signaling, and cell adhesion.

The structural characteristics of SLCO6A1 show that it has the following characteristics:

1. Highly conserved: SLCO6A1 has a highly conserved sequence in humans and other species, which indicates that it is a pan-biological protein that may play an important role in a variety of physiological processes.
2. Multiple functions: SLCO6A1 plays multiple functions in a variety of physiological processes, including promoting ion transport, regulating cell metabolism, maintaining cell adhesion, etc. This indicates that it is a multifunctional protein with broad application prospects.
3. Potential drug target: SLCO6A1 has a high expression level in vivo, and it plays an important role in a variety of diseases, such as diabetes, kidney disease, liver disease, etc. Therefore, SLCO6A1 is considered a protein with good drug target value.

The relationship between SLCO6A1 and disease

SLCO6A1 plays an important role in a variety of diseases and is therefore considered a very promising drug target. Here are some diseases associated with SLCO6A1:

1. Diabetes: Diabetes is a common metabolic disease, and its pathogenesis is closely related to abnormal cell membrane ion transport. SLCO6A1 plays an important role in the occurrence and development of diabetes. Studies have shown that SLCO6A1 gene expression levels are positively correlated with blood sugar levels in diabetic patients.
2. Kidney disease: Kidney disease is a common disease, and its pathogenesis is closely related to the damage of renal tubules and collecting duct epithelial cells. SLCO6A1 plays an important role in the damage and repair of renal tubular and collecting duct epithelial cells. Studies have shown that SLCO6A1 gene expression level is positively correlated with the degree of damage to renal tubular and collecting duct epithelial cells.
3. Liver disease: Liver disease is a common metabolic disease, and its pathogenesis is closely related to abnormal ion transport in the liver cell membrane. SLCO6A1 plays an important role in abnormal ion transport in liver cell membranes. Studies have shown that the expression level of SLCO6A1 gene is positively correlated with the degree of abnormal ion transport in liver cell membranes.

Clinical application prospects of SLCO6A1

SLCO6A1 plays an important role in a variety of diseases and therefore has broad clinical application prospects. Here are some possible SLCO6A1-targeting drugs:

1. Anti-diabetic drugs: SLCO6A1 gene expression levels are positively correlated with blood sugar levels in diabetic patients. Therefore, antidiabetic drugs may consider SLCO6A1 as a therapeutic target. At present, some anti-diabetic drugs such as metformin and glaqidone have shown inhibitory effects on SLCO6A1, but the efficacy of these drugs still needs to be further improved.
2. Anti-kidney disease drugs: The expression level of SLCO6A1 gene is positively correlated with the degree of damage to renal tubule and collecting duct epithelial cells. Therefore, anti-kidney disease drugs may consider SLCO6A1 as a therapeutic target. At present, some anti-renal disease drugs such as amiloride and belipril have shown inhibitory effects on SLCO6A1, but the efficacy of these drugs still needs to be further improved.
3. Anti-liver disease drugs: SLCO6A1 gene

Protein Name: Solute Carrier Organic Anion Transporter Family Member 6A1

The "SLCO6A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLCO6A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets